Who Exports Meloxicam from India — 277 Suppliers Behind a $199.4M Market
India's meloxicam export market is supplied by 277 active exporters who collectively shipped $199.4M across 3,297 shipments. UNICHEM LABORATORIES LIMITED leads with a 71.0% market share, followed by CIPLA LIMITED and ZYDUS LIFESCIENCES LIMITED. The top 5 suppliers together control 92.1% of total export value, reflecting a concentrated market structure.
Top Meloxicam Exporters from India — Ranked by Export Value
UNICHEM LABORATORIES LIMITED is the leading meloxicam exporter from India, holding a 71.0% share of the $199.4M market across 3,297 shipments from 277 exporters. The top 5 suppliers — UNICHEM LABORATORIES LIMITED, CIPLA LIMITED, ZYDUS LIFESCIENCES LIMITED, LUPIN LIMITED, VANTAGE INTERNATIONAL (INDIA) INC — collectively control 92.1% of total export value, indicating a highly concentrated market. Individual shares are: UNICHEM LABORATORIES LIMITED (71.0%), CIPLA LIMITED (14.4%), ZYDUS LIFESCIENCES LIMITED (3.1%), LUPIN LIMITED (2.4%), VANTAGE INTERNATIONAL (INDIA) INC (1.2%).
Top Meloxicam Exporters from India
Ranked by export value · 277 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | UNICHEM LABORATORIES LIMITED PHARMA : MELOXICAM 15MG TABLETS - 7308 BTLS X 1000 TABSPHARMA : MELOXICAM 15MG TABLETS - 7164 BTLS X 1000 TABSMELOXICAM 15MG TABLETS | $141.5M | 13 | 71.0% |
| 2 | CIPLA LIMITED PHARMA : MELOXICAM 15MG TABLETS - 7308 BTLS X 1000 TABSPHARMA : MELOXICAM 15MG TABLETS - 7164 BTLS X 1000 TABSMELOXICAM TABS USP 15MG NDC NO.6909715907 ANDA NO. 77929 | $28.7M | 8 | 14.4% |
| 3 | ZYDUS LIFESCIENCES LIMITED PHARMA : MELOXICAM 15MG TABLETS - 7308 BTLS X 1000 TABSPHARMA : MELOXICAM 15MG TABLETS - 7164 BTLS X 1000 TABSMELOXICAM TABS USP 15MG NDC NO.6909715907 ANDA NO. 77929 | $6.2M | 4 | 3.1% |
| 4 | LUPIN LIMITED PHARMA : MELOXICAM 15MG TABLETS - 7308 BTLS X 1000 TABSPHARMA : MELOXICAM 15MG TABLETS - 7164 BTLS X 1000 TABSMELOXICAM TABS USP 15MG NDC NO.6909715907 ANDA NO. 77929 | $4.7M | 1 | 2.4% |
| 5 | VANTAGE INTERNATIONAL (INDIA) INC AZEROVEE TABORTHOPAIN-15 TABLETORTHOPAIN-15 TABLETS (MELOXICAM BP 15MG | $2.5M | 1 | 1.2% |
| 6 | MACLEODS PHARMACEUTICALS LTD MELOCAM 7.5 10X10SMOOV 7.5 (EACH FILM COATED TABLET CONTAINS:MELOXICAM B.P. 7.5MG | $1.3M | 3 | 0.6% |
| 7 | AUROBINDO PHARMA LTD MELOXICAM 15MG TABLETS PACK OF 3X10TMUVERA 15 TABLETSHARMLESS MEDICINES MELOXICAM (FLEXOCAM | $1.1M | 13 | 0.5% |
| 8 | GRACURE PHARMACEUTICALS LIMITED MELOXICAM SANDOZ 15MG CAPSULES( MELOXICAMELOXICAM SANDOZ 15 MG TABLET. (INV.QTYMELOXICAM SANDOZ 7.5 MG TABLET (MELOXICA | $1.0M | 1 | 0.5% |
| 9 | CADILA HEALTHCARE LIMITED PHARMA : MELOXICAM 15MG TABLETS - 7308 BTLS X 1000 TABSPHARMA : MELOXICAM 15MG TABLETS - 7164 BTLS X 1000 TABSMELOXICAM TABS USP 15MG NDC NO.6909715907 ANDA NO. 77929 | $1.0M | 3 | 0.5% |
| 10 | ATHENA DRUG DELIVERY SOLUTIONS PRIVATE LIMITED MELOCOX ODT 15MG 5CPR AG | $901.8K | 2 | 0.5% |
| 11 | STRIDES PHARMA SCIENCE LIMITED MELOXICAM SANDOZ 15MG CAPSULES( MELOXICAMELOXICAM SANDOZ 15 MG TABLET. (INV.QTYMELOXICAM SANDOZ 7.5 MG TABLET (MELOXICA | $781.6K | 2 | 0.4% |
| 12 | BRAWN LABORATORIES LIMITED MELOCAM 7.5 10X10SMOOV 7.5 (EACH FILM COATED TABLET CONTAINS:MELOXICAM B.P. 7.5MG | $738.4K | 5 | 0.4% |
| 13 | ZIM LABORATORIES LIMITED. MELOCAM 7.5 10X10SMOOV 7.5 (EACH FILM COATED TABLET CONTAINS:MELOXICAM B.P. 7.5MG | $564.4K | 4 | 0.3% |
| 14 | PROSFORA TECHNOLOGIES PRIVATE LIMITED MELOXICAM 15MG TABLESMELOXICAM 7.5MG TABLESMELOXICAM 7.5MG TABLETS 3X10TNOS | $538.9K | 1 | 0.3% |
| 15 | CADILA HEALTHCARE LTD PHARMA : MELOXICAM 15MG TABLETS - 7308 BTLS X 1000 TABSPHARMA : MELOXICAM 15MG TABLETS - 7164 BTLS X 1000 TABSMELOXICAM TABS USP 15MG NDC NO.6909715907 ANDA NO. 77929 | $538.8K | 1 | 0.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Meloxicam exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Cipla Limited | Approved | Yes | Yes | Not specified | Cipla is a WHO GMP-certified company in India. |
| Aurobindo Pharma Limited | Approved | Yes | Yes | 41 (Jan–Sept 2023) | Aurobindo Pharma is a WHO GMP-certified company in India. |
| Lupin Limited | Approved | Yes | Yes | 15 (Jan–Sept 2023) | Lupin is a WHO GMP-certified company in India. |
| Macleods Pharmaceuticals Ltd | Approved | Yes | Yes | 10 (Jan–Sept 2023) | Macleods Pharmaceuticals is a WHO GMP-certified company in India. |
| Cadila Pharmaceuticals Limited | Approved | Yes | Yes | Not specified | Cadila Pharmaceuticals is a WHO GMP-certified company in India. |
| Zydus Lifesciences Limited | Approved | Yes | Yes | 59 (Jan–Sept 2023) | Zydus Lifesciences is a WHO GMP-certified company in India. |
| Strides Pharma Science Limited | Approved | Yes | Yes | Not specified | Strides Pharma Science is a WHO GMP-certified company in India. |
| Unichem Laboratories Limited | Approved | Yes | Yes | Not specified | Unichem Laboratories' facilities are approved by USFDA and other major health au |
| Gracure Pharmaceuticals Limited | Not Listed | Yes | Yes | Not specified | Gracure Pharmaceuticals is a WHO GMP-certified company in India. |
TransData Nexus reviewed the regulatory standing of 9 leading Meloxicam exporters from India. 8 hold US FDA facility approvals, 9 maintain WHO-GMP certification, and 9 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Meloxicam sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% to the nation's bulk drug production. The city hosts numerous pharmaceutical companies specializing in Active Pharmaceutical Ingredients (APIs) and intermediates. For instance, SVK Laboratories Private Limited, established in 2007, focuses on manufacturing bulk drugs and fine chemicals, adhering to Good Manufacturing Practices (GMP) and international standards. Similarly, Vasudha Pharma Chem Limited, located in Jeedimetla, Hyderabad, is known for producing bulk drugs and intermediates.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. Vadodara, in particular, hosts companies like Mercury Laboratories Limited, which has been manufacturing a diverse range of pharmaceutical products for over five decades. Additionally, the region is home to Alembic Pharmaceuticals, an Indian multinational company headquartered in Vadodara, specializing in both APIs and formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical industry. This region houses numerous pharmaceutical companies with significant export operations, leveraging Mumbai's strategic port facilities to distribute products globally. The presence of major pharmaceutical firms in this area underscores its importance in the international pharmaceutical supply chain.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, primarily due to favorable tax incentives. The region attracts numerous pharmaceutical companies seeking cost-effective production solutions, contributing significantly to India's pharmaceutical output.
5Sourcing Recommendations
- Diversify Supplier Base: While Unichem Laboratories Limited dominates Meloxicam exports, consider engaging with other top suppliers like Cipla Limited and Zydus Lifesciences Limited to mitigate supply chain risks.
- Evaluate Regional Capabilities: Assess the specific strengths of each pharmaceutical cluster—Hyderabad for bulk drugs, Ahmedabad-Vadodara for formulations, and Mumbai-Thane-Raigad for export logistics—to align sourcing strategies with production needs.
- Leverage Tax Incentives: Explore manufacturing partnerships in tax incentive zones like Baddi-Nalagarh to optimize production costs.
- Ensure Regulatory Compliance: Prioritize suppliers with GMP certifications and a track record of adhering to international quality standards to maintain product integrity and regulatory compliance.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Meloxicam exporters from India
Unichem Laboratories Limited — Ipca Laboratories acquires 26% stake in Unichem Laboratories
Ipca Laboratories Limited announced an open offer to acquire up to 26% of the fully diluted equity share capital of Unichem Laboratories Limited, aiming to strengthen its position in the pharmaceutical sector. - IMPACT: This acquisition is expected to enhance Unichem's operational capabilities, potentially increasing its Meloxicam production and export capacity.
Impact: This acquisition is expected to enhance Unichem's operational capabilities, potentially increasing its Meloxicam production and export capacity.
Zydus Lifesciences Limited — Zydus receives USFDA approval for prostate cancer drug
Zydus Lifesciences received approval from the US Food and Drug Administration (USFDA) to manufacture enzalutamide tablets, used for treating prostate cancer, at its Ahmedabad facility. - IMPACT: While this approval pertains to oncology, it may lead to increased production capabilities that could indirectly benefit Meloxicam exports.
Impact: While this approval pertains to oncology, it may lead to increased production capabilities that could indirectly benefit Meloxicam exports.
Zydus Lifesciences Limited — Zydus acquires 50% stake in Sterling Biotech Limited
Zydus Lifesciences, through its subsidiary, acquired a 50% equity stake in Sterling Biotech Limited, a company specializing in gelatin and select active pharmaceutical ingredients, marking Zydus's entry into specialized biotech products. - IMPACT: This acquisition may enhance Zydus's API production capabilities, potentially impacting Meloxicam manufacturing and exports.
Impact: This acquisition may enhance Zydus's API production capabilities, potentially impacting Meloxicam manufacturing and exports.
Common Questions — Meloxicam Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which meloxicam supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, UNICHEM LABORATORIES LIMITED leads with 368 recorded shipments worth $141.5M. CIPLA LIMITED (889 shipments) and ZYDUS LIFESCIENCES LIMITED (184 shipments) are also established high-volume exporters.
Q How many meloxicam manufacturers are there in India?
India has 277 active meloxicam exporters with a combined export market of $199.4M across 3,297 shipments to 100 countries. The top 5 suppliers hold 92.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for meloxicam from India?
Average FOB unit price: $1.58 per unit, ranging from $0.00 to $221.74. Average shipment value: $60.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 277 verified Indian exporters of Meloxicam ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,297 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 100 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,297 Verified Shipments
277 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists